GH

Guardant Health (GH)

Guardant Health Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:GH

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/01	05 : 25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GH	Guardant Health Inc
2024/05/31	21 : 05	Business Wire	Guardant Health Named to TIME100 Most Influential Companies	NASDAQ:GH	Guardant Health Inc
2024/05/30	21 : 05	Business Wire	Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening	NASDAQ:GH	Guardant Health Inc
2024/05/24	20 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GH	Guardant Health Inc
2024/05/24	08 : 03	Business Wire	FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option	NASDAQ:GH	Guardant Health Inc
2024/05/23	20 : 05	Business Wire	Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening	NASDAQ:GH	Guardant Health Inc
2024/05/23	05 : 05	Business Wire	Guardant Health to Participate in Upcoming Investor Conferences	NASDAQ:GH	Guardant Health Inc
2024/05/21	21 : 44	Business Wire	Guardant Health reçoit la certification IVDR de l’UE pour la biopsie liquide Guardant360® CDx destinée au profilage des mutations tumorales dans tous les cancers solides et les indications de diagnostic compagnon	NASDAQ:GH	Guardant Health Inc
2024/05/21	21 : 44	Business Wire	Guardant Health erhält EU-IVDR-Zertifizierung für Flüssigbiopsie Guardant360® CDx zur Erstellung von Tumormutationsprofilen für alle soliden Krebsarten und therapiebegleitende Diagnostika-Indikationen	NASDAQ:GH	Guardant Health Inc
2024/05/21	21 : 05	Business Wire	Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications	NASDAQ:GH	Guardant Health Inc
2024/05/17	21 : 05	Business Wire	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:GH	Guardant Health Inc
2024/05/17	07 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GH	Guardant Health Inc
2024/05/17	07 : 12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GH	Guardant Health Inc
2024/05/16	21 : 05	Business Wire	Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week	NASDAQ:GH	Guardant Health Inc
2024/05/10	05 : 59	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:GH	Guardant Health Inc
2024/05/10	05 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GH	Guardant Health Inc
2024/05/10	05 : 05	Business Wire	Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance	NASDAQ:GH	Guardant Health Inc
2024/05/08	05 : 05	Business Wire	Guardant Health to Participate in Upcoming Investor Conferences	NASDAQ:GH	Guardant Health Inc
2024/05/07	21 : 00	Business Wire	Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone	NASDAQ:GH	Guardant Health Inc
2024/05/07	06 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GH	Guardant Health Inc
2024/05/07	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GH	Guardant Health Inc
2024/05/07	06 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GH	Guardant Health Inc
2024/04/22	21 : 52	Business Wire	FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23	NASDAQ:GH	Guardant Health Inc
2024/04/19	05 : 05	Business Wire	Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024	NASDAQ:GH	Guardant Health Inc
2024/04/03	21 : 05	Business Wire	Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	NASDAQ:GH	Guardant Health Inc
2024/03/14	06 : 00	Business Wire	Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine	NASDAQ:GH	Guardant Health Inc
2024/03/07	06 : 30	Business Wire	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:GH	Guardant Health Inc
2024/03/06	10 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GH	Guardant Health Inc
2024/03/05	08 : 39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GH	Guardant Health Inc
2024/03/05	08 : 37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:GH	Guardant Health Inc